A Billion Dollar Market At Your Fingertips. Literally

Transcription

1 A Billion Dollar Market At Your Fingertips Literally

2 Billion Dollar Problem How long does it take for these nails to be cured on their own? NEVER! 1

3 Billion Dollar Problem About 10% of the population is affected Leads to: Nail deformation, discoloration, thickening, pain, and social embarrassment 95% of Onychomycosis infections are of the toenails 2

4 Billion Dollar Problem 35 million people in the US are affected by Onychomycosis 47% of patients are not receiving treatment US represents 35% of the $1 Billion market or $350 Million 47% NO Treatment 53% 3

5 Current Solution The cure can be worse than the disease! Current standard of care is only 38% efficacy Disadvantages: Oral medication leading to systemic side effects (liver toxicity) Liver function testing Other negative effects on resources¹ 4

6 Current Solution Lamisil and generics Disadvantages: Liver toxicity Only 38% efficacy rate (standard of care) Dangerous interaction with medication and food High relapse rate¹ Global Sales: $1.2 Billion (2004), $500 Million (2012) 1.4 Million new prescriptions per year in the US alone (2010) 5

7 Current Solution Penlac and generics Disadvantages: Only 8% efficacy rate Does not penetrate the nail structure Need to use nail polish remover Prescriptions: 350,000 new prescriptions per year in the US (2010) 6

8 Other Competitors Sporanox and generics by Janssen Liver toxicity Under Development: Anacor for GSK Azole by Valeant 7

9 Billion Dollar Opportunity $2.1 Billion market at your fingertips 7% market annual growth rate $3.4 Billion market by 2017 Still : Medical need is not met 8

10 Billion Dollar Opportunity Market size: approx. 10% of the population RichPoint Pharma Opportunity: $1 Billon per year Most important revenue markets: North America, Western Europe, Japan, Australia, BRICK countries, and Middle East Gulf States. 9

11 The Breakthrough Solution RAF02 A BREAKTHROUGH technology for the treatment of nail fungus *Higher efficacy *Better tolerability 10

12 The Breakthrough Solution: RAF02 Higher efficacy rate, 100% clear nail results* Better tolerability No reported side effects* Sustained release No relapse reported *Based on 2012 Case Study 11

13 The Breakthrough Solution: RAF02 All ingredients FDA approved No interaction with medications/food No strain on medical resources No need for nailpolish remover 12

14 Proof Of Concept 2012 Case Study: 15 patients with Onychomycosis used RAF02 Results: 100% success rate with all 15 patients No reported side effects Before RAF02 After RAF02 13

15 The RAF02 Team Samy Saad, RPh: Clinical Pharmacist, Founder & Director Mike Fenwick, MSc, LLB: IP Counsel Irwin Steinberg, LLB: Corporate Counsel James Sbrolla: Commercialization Advisor, RIC Centre Ramzy George, BBA: Strategic Business Advisor Sam Boles, BSc, RPh: Marketing Advisor Doug Crawford, PhD: Scientific Advisor Being Recruited: Key Opinion Leaders in Dermatology 14

16 Business Model Out-licensing, globally or regionally with: Sign-on payment, milestone payments, and royalties¹ Next Steps: Scaling-Up in Other Indications ² Partnering with other pharmaceutical companies 15

17 Investment Capital $500,000 for: Regional IP filing Stability Studies Clinical Trials Marketing to Pharmaceutical companies 16

18 THANK YOU Questions? Samy Saad, R.Ph. Managing Director, RichPoint Pharma (416)

19 A Billion Dollar Market At Your Fingertips Literally